Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C4221023: Encorafenib + Binimetinib + Pembrolizumab vs Nivolumab + Ipilimumab in BRAF V600E/K Melanoma After Anti–PD-1
2023-509471-17-00Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial in melanoma comparing Encorafenib + Binimetinib + Pembrolizumab with Nivolumab + Ipilimumab (2 arms). Primary endpoint: Objective response rate (ORR). Started Jun 2024; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2023-509471-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509471-17-00.